Eisai Concludes Japan License Agreement for New Aricept Transdermal Formulation - Drugs.com MedNews
Links shared publicly online about this topic.
- 507total visits
Eisai Concludes Japan License Agreement for New Aricept Transdermal Formulation - Drugs.com MedNews
TOKYO, Feb. 14, 2011-Eisai Co., Ltd. (Headquarters Tokyo, President CEO Haruo Naito) announced today that it has concluded an exclusive license agreement with T
View full resource at drugs.com
Tags: Alzheimer's Disease Medication, Drug, Aricept, Eisai
Most Recently Shared on February 14, 2011 at 3:17 pm By:
Eisai Concludes Japan License Agreement for New Aricept Transdermal Formulation: TOKYO, Feb. 14, 2011-Eisa... http://bit.ly/e7loN2 #drug
Advertisement
